These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

704 related items for PubMed ID: 32240727

  • 1. PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a).
    Watts GF, Chan DC, Pang J, Ma L, Ying Q, Aggarwal S, Marcovina SM, Barrett PHR.
    Metabolism; 2020 Jun; 107():154221. PubMed ID: 32240727
    [Abstract] [Full Text] [Related]

  • 2. PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statin-treated patients with very high apolipoprotein(a) concentration.
    Ying Q, Chan DC, Pang J, Marcovina SM, Barrett PHR, Watts GF.
    J Intern Med; 2022 Jun; 291(6):870-876. PubMed ID: 35112754
    [Abstract] [Full Text] [Related]

  • 3. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.
    Watts GF, Chan DC, Somaratne R, Wasserman SM, Scott R, Marcovina SM, Barrett PHR.
    Eur Heart J; 2018 Jul 14; 39(27):2577-2585. PubMed ID: 29566128
    [Abstract] [Full Text] [Related]

  • 4. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.
    Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, Karmally W, Nandakumar R, Fontanez N, Obunike J, Marcovina SM, Lichtenstein AH, Matthan NR, Matta J, Maroccia M, Becue F, Poitiers F, Swanson B, Cowan L, Sasiela WJ, Surks HK, Ginsberg HN.
    Circulation; 2017 Jan 24; 135(4):352-362. PubMed ID: 27986651
    [Abstract] [Full Text] [Related]

  • 5. PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate.
    Croyal M, Tran TT, Blanchard RH, Le Bail JC, Villard EF, Poirier B, Aguesse A, Billon-Crossouard S, Ramin-Mangata S, Blanchard V, Nativel B, Chemello K, Khantalin I, Thedrez A, Janiak P, Krempf M, Boixel C, Lambert G, Guillot E.
    Clin Sci (Lond); 2018 May 31; 132(10):1075-1083. PubMed ID: 29724769
    [Abstract] [Full Text] [Related]

  • 6. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI, Ezhov MV, Razova OA, Afanasieva MI, Utkina EA, Pokrovsky SN.
    Atherosclerosis; 2018 Oct 31; 277():477-482. PubMed ID: 30270088
    [Abstract] [Full Text] [Related]

  • 7. Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?
    Reiner Ž.
    Curr Atheroscler Rep; 2019 Mar 07; 21(4):14. PubMed ID: 30847681
    [Abstract] [Full Text] [Related]

  • 8. Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy.
    Chan DC, Watts GF, Coll B, Wasserman SM, Marcovina SM, Barrett PHR.
    J Am Heart Assoc; 2019 Apr 02; 8(7):e011781. PubMed ID: 30897995
    [Abstract] [Full Text] [Related]

  • 9. Fractional turnover of apolipoprotein(a) and apolipoprotein B-100 within plasma lipoprotein(a) particles in statin-treated patients with elevated and normal Lp(a) concentration.
    Ma L, Chan DC, Ooi EMM, Barrett PHR, Watts GF.
    Metabolism; 2019 Jul 02; 96():8-11. PubMed ID: 30995439
    [Abstract] [Full Text] [Related]

  • 10. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K, Sharma M, Ferdinand KC.
    Nutr Metab Cardiovasc Dis; 2016 Oct 02; 26(10):853-62. PubMed ID: 27352986
    [Abstract] [Full Text] [Related]

  • 11. Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy.
    Koren MJ, Kereiakes D, Pourfarzib R, Winegar D, Banerjee P, Hamon S, Hanotin C, McKenney JM.
    J Am Heart Assoc; 2015 Nov 19; 4(11):. PubMed ID: 26586732
    [Abstract] [Full Text] [Related]

  • 12. Apolipoprotein(a) Kinetics in Statin-Treated Patients With Elevated Plasma Lipoprotein(a) Concentration.
    Ma L, Chan DC, Ooi EMM, Marcovina SM, Barrett PHR, Watts GF.
    J Clin Endocrinol Metab; 2019 Dec 01; 104(12):6247-6255. PubMed ID: 31393573
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.
    Kereiakes DJ, Lepor NE, Gerber R, Veronica Lee L, Elassal J, Thompson D, Michael Gibson C.
    Atherosclerosis; 2018 Oct 01; 277():211-218. PubMed ID: 30025648
    [Abstract] [Full Text] [Related]

  • 14. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
    Dixon DL, Pamulapati LG, Bucheit JD, Sisson EM, Smith SR, Kim CJ, Wohlford GF, Pozen J.
    Curr Atheroscler Rep; 2019 Mar 16; 21(5):16. PubMed ID: 30877491
    [Abstract] [Full Text] [Related]

  • 15. Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II.
    Leiter LA, Zamorano JL, Bujas-Bobanovic M, Louie MJ, Lecorps G, Cannon CP, Handelsman Y.
    Diabetes Obes Metab; 2017 Jul 16; 19(7):989-996. PubMed ID: 28206704
    [Abstract] [Full Text] [Related]

  • 16. The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab.
    Enkhmaa B, Anuurad E, Zhang W, Yue K, Li CS, Berglund L.
    J Lipid Res; 2017 Oct 16; 58(10):2008-2016. PubMed ID: 28798072
    [Abstract] [Full Text] [Related]

  • 17. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
    Damask A, Steg PG, Schwartz GG, Szarek M, Hagström E, Badimon L, Chapman MJ, Boileau C, Tsimikas S, Ginsberg HN, Banerjee P, Manvelian G, Pordy R, Hess S, Overton JD, Lotta LA, Yancopoulos GD, Abecasis GR, Baras A, Paulding C, Regeneron Genetics Center and the ODYSSEY OUTCOMES Investigators.
    Circulation; 2020 Feb 25; 141(8):624-636. PubMed ID: 31707832
    [Abstract] [Full Text] [Related]

  • 18. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
    Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, Kim YU, Jukema JW, Pordy R, Roe MT, White HD, Bhatt DL, ODYSSEY OUTCOMES Committees and Investigators*.
    Circulation; 2020 May 19; 141(20):1608-1617. PubMed ID: 32223446
    [Abstract] [Full Text] [Related]

  • 19. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J, Poitiers F, Paehler T, Brunet A, DiCioccio AT, Cannon CP, Surks HK, Pinquier JL, Hanotin C, Sasiela WJ.
    J Am Heart Assoc; 2016 Jun 10; 5(6):. PubMed ID: 27287699
    [Abstract] [Full Text] [Related]

  • 20. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR, Kohli P, Giugliano RP, O'Donoghue ML, Somaratne R, Zhou J, Hoffman EB, Huang F, Rogers WJ, Wasserman SM, Scott R, Sabatine MS.
    Circulation; 2013 Aug 27; 128(9):962-9. PubMed ID: 23884353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.